Abstract
Tumor-specific drug delivery represents a challenging issue that restricts the clinical applications of many advanced anticancer therapeutics. Ovarian cancer exhibits a quite specific pattern of dissemination: it spreads primarily within the peritoneal cavity, providing a possibility of locoregional, intraperitoneal drug administration. Considering this unique aspect of ovarian cancer biology, this chapter provides a short review of most promising approaches for therapeutic delivery of genetic drugs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sultana S, Khan MR, Kumar M, Kumar S, Ali M (2013) Nanoparticles-mediated drug delivery approaches for cancer targeting: a review. J Drug Target 21(2):107–125. doi:10.3109/1061186X.2012.712130
Diou O, Tsapis N, Fattal E (2012) Targeted nanotheranostics for personalized cancer therapy. Expert Opin Drug Deliv 9:1475–1487
Hirsjarvi S, Passirani C, Benoit JP (2011) Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol 8:188–196
Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ (2012) Cell–cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev 31:397–414
Hasovits C, Clarke S (2012) Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin Pharmacokinet 51:203–224
Ceelen WP, Flessner MF (2010) Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 7:108–115
Zahedi P, Yoganathan R, Piquette-Miller M, Allen C (2012) Recent advances in drug delivery strategies for treatment of ovarian cancer. Expert Opin Drug Deliv 9:567–583
Kanerva A, Raki M, Hemminki A (2007) Gene therapy of gynaecological diseases. Expert Opin Biol Ther 7:1347–1361
Tros de Ilarduya C, Sun Y, Duzgunes N (2010) Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci 40:159–170
Garcia L, Urbiola K, Duzgunes N, Tros de Ilarduya C (2012) Lipopolyplexes as nanomedicines for therapeutic gene delivery. Methods Enzymol 509:327–338
Malek A, Merkel O, Fink L, Czubayko F, Kissel T et al (2009) In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol 236:97–108
Hobel S, Koburger I, John M, Czubayko F, Hadwiger P et al (2010) Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 12:287–300
Mangala LS, Han HD, Lopez-Berestein G, Sood AK (2009) Liposomal siRNA for ovarian cancer. Methods Mol Biol 555:29–42
Tasciotti E, Liu X, Bhavane R, Plant K, Leonard AD et al (2008) Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol 3:151–157
Chiappini C, Tasciotti E, Fakhoury JR, Fine D, Pullan L et al (2010) Tailored porous silicon microparticles: fabrication and properties. Chemphyschem 11:1029–1035
Godin B, Tasciotti E, Liu X, Serda RE, Ferrari M (2011) Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res 44:979–989
Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP et al (2010) Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 70:3687–3696
Liu X, Suo R, Xiong SL, Zhang QH, Yi GH (2012) HDL drug carriers for targeted therapy. Clin Chim Acta 415C:94–100
Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J et al (2011) Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13:309–319
Nakayama T, Butler JS, Sehgal A, Severgnini M, Racie T et al (2012) Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles. Mol Ther 20:1582–1589
Ding Y, Wang W, Feng M, Wang Y, Zhou J et al (2012) A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 33:8893–8905
Bang C, Thum T (2012) Exosomes: new players in cell–cell communication. Int J Biochem Cell Biol 44:2060–2064
Vickers KC, Remaley AT (2012) Lipid-based carriers of microRNAs and intercellular communication. Curr Opin Lipidol 23:91–97
Ohno S, Ishikawa A, Kuroda M (2013) Roles of exosomes and microvesicles in disease pathogenesis. Adv Drug Deliv Rev 65(3):398–401. doi:10.1016/j.addr.2012.07.019
Martins VR, Dias MS, Hainaut P (2013) Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol 25(1):66–75. doi:10.1097/CCO.0b013e32835b7c81
El-Andaloussi S, Lee Y, Lakhal-Littleton S, Li J, Seow Y et al (2012) Exosome-mediated delivery of siRNA in vitro and in vivo. Nat Protoc 7:2112–2126
El Andaloussi S, Lakhal S, Mager I, Wood MJ (2013) Exosomes for targeted siRNA delivery across biological barriers. Adv Drug Deliv Rev 65(3):391–397. doi: 10.1016/j.addr.2012.08.008
Peng P, Yan Y, Keng S (2011) Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity. Oncol Rep 25:749–762
Escrevente C, Keller S, Altevogt P, Costa J (2011) Interaction and uptake of exosomes by ovarian cancer cells. BMC Cancer 11:108
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, New York
About this protocol
Cite this protocol
Malek, A. (2013). Drug Delivery Approaches for Ovarian Cancer Therapy. In: Malek, A., Tchernitsa, O. (eds) Ovarian Cancer. Methods in Molecular Biology, vol 1049. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-547-7_33
Download citation
DOI: https://doi.org/10.1007/978-1-62703-547-7_33
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-546-0
Online ISBN: 978-1-62703-547-7
eBook Packages: Springer Protocols